Results 111 to 120 of about 1,514,542 (307)

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Tolerance Analysis and Optimization of Static Assembly of RV Reducer based on 3DCS

open access: yesJixie chuandong, 2019
In order to improve the assembly yield of RV reducer, combined with its assembly dimension chain design parts tolerance,the use of CATIA is for three-dimensional modeling of RV reducer.
Xiongwei Xie, Honghai Xu, Tong Guan
doaj  

Allelic diversity at orthologous candidate genes for drought tolerance in cereal crops: Example of the ASR gene family [PDF]

open access: yes, 2008
Drought is a major abiotic stress. Many candidate genes have been proposed during the last years to explain aspects of tolerance to drought stress, for a specific crop and in a specific environment.
Baum, Michaël   +8 more
core  

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

DICE Fault Injection Tool

open access: yes, 2016
In this paper, we describe the motivation, innovation, design, running example and future development of a Fault Inject Tool (FIT). This tool enables controlled causing of cloud platform issues such as resource stress and service or VM outages, the ...
Artač, Matej   +2 more
core   +1 more source

Molecular cancer prevention: Intercepting disease

open access: yesMolecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco   +2 more
wiley   +1 more source

二阶矩可靠性指标的计算机辅助公差优化装配尺寸链设计模型

open access: yesJixie chuandong, 2008
Optimum tolerance design is one of important steps in the process of machine design and manufacture and in the application of computer,and model-building is an important step.Thus a kind of computer aided optimum tolerance design model is built,by the ...
张帆
doaj  

Design of Docking Interfaces for On-Orbit Assembly of Large Structures in Space

open access: yesSensors
Considering the complexity of on-orbit assembly during space missions and the super-large size of space structures, this paper presents the design for a new type of docking interface with an androgynous body that exhibits a number of advantages ...
Shuai Liu   +3 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy